We are pleased to share a copy of the latest research report from MST Access, which has increased its valuation for Race Oncology from $4.16 to A$5.29 per share (undiluted).

The report states, “The company is expanding its pipeline with both broader applications (specifically, the RNA pathway) and deeper opportunities for current formulations (notably, the cardioprotective opportunity). We believe this diversified pipeline, funded with a capital raising of $29.7m, has strong potential for value creation and that news flow across its key focus areas will create multiple share price catalysts over the medium term.”

Click to read the report. We welcome any comments or questions. Our team will endeavour to get back to all questions as soon as we can.